Skip to main content
Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Nastoupil, L. J., Bonner, A., Wang, P., Almuallem, L., Desai, J., Fasan, O., Farazi, T., Kumar, J., Dahiya, S. AMER SOC HEMATOLOGY. 2023

View details for DOI 10.1182/blood-2023-178786

View details for Web of Science ID 001159740300039